+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.

Age: 16Years - 80YearsAll GendersPhase 3
171 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.

Age: 18Years +All GendersPhase 3
145 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.

Age: 16Years - 80YearsAll GendersPhase 3
461 locations
P

Actively Recruiting

Researchers are studying the effects of duvakitug in adults and older teenagers with moderately to severely active Ulcerative Colitis UC, a condition causing inflammation in the colon. This Phase 3 clinical trial is designed to evaluate both the effectiveness and safety of this treatment compared to placebo injections. The study is randomized, double-blind, and takes place at multiple international centers to ensure reliable results. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The trial includes a screening period followed by a 12-week initial treatment phase, with an additional 12-week extended induction period for those who do not respond initially. Participants who do not join the maintenance study will have a 45-day follow-up visit after completing the induction phases. During the study, participants will attend up to 8 visits in the initial treatment phases and up to 15 visits if they continue to the extended induction period. Researchers will assess clinical remission rates, endoscopic improvement, symptom responses, quality of life scores, and safety outcomes such as adverse events and immune responses to the drug. The total study participation may last up to 35 weeks, allowing close monitoring of health and treatment effects throughout.

Age: 16Years - 80YearsAll GendersPhase 3
240 locations
O

Actively Recruiting

Crohns disease is a chronic inflammatory condition affecting the digestive tract and is currently incurable. This research aims to evaluate how safe and effective the drug upadacitinib is for treating moderately to severely active Crohns disease in real-world settings. The study will monitor any adverse events and track changes in disease activity among participants. All participants will receive upadacitinib as prescribed by their own doctors according to approved local guidelines. The study plans to enroll about 240 participants in Japan who have recently started upadacitinib treatment. Treatment will follow routine clinical practice without altering the prescribed approach. Participants will be followed for up to 64 weeks with visits that may occur in person or virtually, aligned with standard care. Researchers will assess outcomes such as the percentage of participants experiencing serious infections related to the drug. There is expected to be no extra burden beyond usual medical care throughout the study period.

Age: 15Years +All Genders
104 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of surovatamig AZD0486 as a monotherapy in adolescents and adults aged 12 years and above with relapsed or refractory B-cell Acute Lymphoblastic Leukemia B-ALL. This Phase 12, global, open-label, single-arm study consists of four parts focusing on dose escalation, dose optimization, dose expansion, and efficacy expansion in participants with varying prior treatments and disease status. Participants will receive intravenous infusions of surovatamig AZD0486 across different study parts. Part A involves dose escalation in participants with at least three prior therapies Part B focuses on dose optimization with randomization to two dose levels Part C includes dose expansion with the selected optimal dose and Part D enrolls participants with at least one prior therapy, randomized to two dose levels. The study evaluates safety, tolerability, and efficacy throughout these phases. During the trial, participants will be closely monitored through safety evaluations, response assessments including complete remission rates within three 28-day cycles, and extensive pharmacokinetic and pharmacodynamic analyses. Researchers will assess adverse events, duration of remission, event-free survival, overall survival, and other clinical outcomes for up to 57 months. The study includes ongoing safety monitoring from consent through data cutoff, with an average of six months safety evaluation for later parts. Participants progress and treatment responses will be carefully assessed to determine the recommended phase 2 dose and clinical activity of surovatamig.

Age: 12Years +All GendersPhase 1Phase 2
83 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of a combination treatment including cevostamab, pomalidomide, and dexamethasone compared to the current standard of care in adults with multiple myeloma. Participants have previously received one to three treatments and were exposed to anti-CD38 monoclonal antibodies and lenalidomide, addressing the need for new options after prior therapies. Participants in one group will receive cevostamab intravenously on a 21-day cycle for the first cycle and then every 28 days thereafter, along with oral pomalidomide starting from the second cycle every 28 days. Dexamethasone is given as a premedication before cevostamab. The other group will receive the investigators choice of standard treatment regimens. Both treatments are monitored over an extended period to assess outcomes. Throughout the study, participants will undergo regular evaluations including disease measurements and quality of life assessments using validated questionnaires. Researchers will track responses such as complete remission and progression-free survival for up to five years after enrollment. Safety will be monitored by recording adverse events and treatment tolerability. This long-term follow-up allows comprehensive assessment of treatment impact and participant well-being.

Age: 18Years +All GendersPhase 3
93 locations
M

Actively Recruiting

Researchers are evaluating the efficacy and safety of Eloralintide LY3841136 for adults with osteoarthritis of the knee who are overweight or obese and experiencing knee pain. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess how well Eloralintide works in reducing body weight and improving knee pain. The trial is sponsored by Eli Lilly and Company and includes two independent studies under a master protocol. Participants will receive once-weekly subcutaneous injections of either Eloralintide or placebo. The study includes parallel treatment arms comparing Eloralintide to placebo in adults with osteoarthritis knee pain and weight concerns. Treatment lasts for approximately 64 weeks, with dosing and assessments occurring regularly. The study also allows for a total participation duration of about 75 weeks, including screening. During the trial, participants will undergo various assessments including measurements of body weight, knee pain using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale, physical function, blood pressure, inflammatory markers, and walking distance. Researchers will monitor medication use and collect data on quality of life and biochemical markers. Safety and pharmacokinetics of Eloralintide are also tracked throughout the study.

Age: 18Years +All GendersPhase 3
147 locations

1-10 of 13

1